Welcome to our dedicated page for Cv Sciences SEC filings (Ticker: CVSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CV Sciences, Inc. filings document the regulatory disclosures of an OTCQB consumer wellness company selling hemp-derived CBD products and other natural wellness formulations. Form 8-K reports cover financial results, Regulation FD disclosures, non-GAAP reconciliations and material agreements tied to secured promissory notes.
The company’s filings also describe capital-structure matters, including note purchase agreements, amendments to secured debt, conversion features, maturity provisions, security interests in company assets and intellectual property, and common stock issuance mechanics. Proxy materials cover annual meeting procedures, director elections, stockholder voting matters and governance items for the Delaware corporation.
CV Sciences, Inc. entered into a new note purchase agreement with an institutional investor and issued a secured promissory note with an original principal amount of $600,000. After a $150,000 original issuance discount, a $150,000 payment tied to modifying a prior purchase agreement, and $13,125 of legal and other fees, the Company received net proceeds of $300,000.
The Note is secured by all of the Company’s assets and the assets and intellectual property of its subsidiaries under a Security Agreement and an Intellectual Property Security Agreement dated October 6, 2025. Monthly repayments of $46,153.85 begin on April 6, 2026, with all unpaid amounts due by April 6, 2027, and an 8% discount applies if the Note is fully repaid within six months of closing.
The Note includes customary events of default. On certain events of default, the investor may increase the outstanding balance by 20% or 5%, declare all amounts immediately due, and begin charging interest on the outstanding balance at up to 18% per annum or the maximum rate allowed by law.
CV Sciences, Inc. entered into an agreement with an institutional investor to amend its existing secured promissory note originally issued for a principal amount of $1,600,000.
The amendment extends the note’s maturity to February 12, 2027, revises the monthly principal redemptions to $106,666.67 for the first three months, then zero principal for six months, followed by $106,666.67 for the next twelve months, in each case plus any accrued but unpaid interest. As part of the revised terms, the company also agreed to pay the investor an additional $150,000 in cash, while all other provisions of the original note and purchase agreement remain in effect.
CV Sciences, Inc. entered into an agreement with an institutional investor to amend its existing secured promissory note originally issued for a principal amount of $1,600,000.
The amendment extends the note’s maturity to February 12, 2027, revises the monthly principal redemptions to $106,666.67 for the first three months, then zero principal for six months, followed by $106,666.67 for the next twelve months, in each case plus any accrued but unpaid interest. As part of the revised terms, the company also agreed to pay the investor an additional $150,000 in cash, while all other provisions of the original note and purchase agreement remain in effect.